title: The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation.
abstract: Tianeptine is a clinically used antidepressant that has drawn much attention, because this compound challenges traditional monoaminergic hypotheses of depression. It is now acknowledged that the antidepressant actions of tianeptine, together with its remarkable clinical tolerance, can be attributed to its particular neurobiological properties. The involvement of glutamate in the mechanism of action of the antidepressant tianeptine is consistent with a well-developed preclinical literature demonstrating the key function of glutamate in the mechanism of altered neuroplasticity that underlies the symptoms of depression. This article reviews the latest evidence on tianeptine's mechanism of action with a focus on the glutamatergic system, which could provide a key pathway for its antidepressant action. Converging lines of evidences demonstrate actions of tianeptine on the glutamatergic system, and therefore offer new insights into how tianeptine may be useful in the treatment of depressive disorders.
authors.affiliation: Harold and Margaret Milliken Hatch Laboratory of Neuroendocrinology, The Rockefeller University, New York, NY, USA. mcewen@mail.rockefeller.edu
authors.forename: B S
authors.initials: BS
authors.lastname: McEwen
authors.forename: S
authors.initials: S
authors.lastname: Chattarji
authors.forename: D M
authors.initials: DM
authors.lastname: Diamond
authors.forename: T M
authors.initials: TM
authors.lastname: Jay
authors.forename: L P
authors.initials: LP
authors.lastname: Reagan
authors.forename: P
authors.initials: P
authors.lastname: Svenningsson
authors.forename: E
authors.initials: E
authors.lastname: Fuchs
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology* / Q000627:therapeutic use; D001007:Anxiety / Q000188:drug therapy / Q000378:metabolism; D015306:Biogenic Monoamines / Q000378:metabolism*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D003072:Cognition Disorders / Q000188:drug therapy; D003863:Depression / Q000188:drug therapy / Q000378:metabolism; D004195:Disease Models, Animal; D018698:Glutamic Acid / Q000378:metabolism*; D006801:Humans; D009473:Neuronal Plasticity / Q000187:drug effects; D013315:Stress, Psychological / Q000378:metabolism; D013841:Thiazepines / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D014151:Anti-Anxiety Agents; D000929:Antidepressive Agents, Tricyclic; D015306:Biogenic Monoamines; D013841:Thiazepines; C050504:tianeptine; D018698:Glutamic Acid
references.citation: Behav Neurosci. 1999 Oct;113(5):902-13
references.pmid: 10571474
references.citation: Cell Mol Neurobiol. 2003 Jun;23(3):419-30
references.pmid: 12825836
references.citation: Pol J Pharmacol. 2002 Nov-Dec;54(6):707-10
references.pmid: 12866729
references.citation: Behav Pharmacol. 1991 Feb;2(1):37-46
references.pmid: 11224046
references.citation: Science. 1998 Jan 9;279(5348):222-6
references.pmid: 9422694
references.citation: Neuropharmacology. 1999 Dec;38(12):1831-9
references.pmid: 10608278
references.citation: Hum Psychopharmacol. 2003 Jun;18(4):277-80
references.pmid: 12766932
references.citation: Biol Psychiatry. 2006 Oct 15;60(8):867-73
references.pmid: 16934773
references.citation: Eur J Neurosci. 2007 Dec;26(12):3509-17
references.pmid: 18088278
references.citation: Ann N Y Acad Sci. 2003 Nov;1003:273-91
references.pmid: 14684452
references.citation: Clin Neuropharmacol. 1988;11 Suppl 2:S97-102
references.pmid: 3052827
references.citation: Psychopharmacology (Berl). 2001 Feb;154(1):50-60
references.pmid: 11292006
references.citation: Neuropharmacology. 2003 May;44(6):801-9
references.pmid: 12681378
references.citation: Neurophysiol Clin. 1988 Aug;18(4):369-81
references.pmid: 3185462
references.citation: Biol Psychiatry. 1991 Sep 15;30(6):609-17
references.pmid: 1932408
references.citation: Ann N Y Acad Sci. 2003 Nov;1003:250-72
references.pmid: 14684451
references.citation: J Neurosci. 2005 Mar 30;25(13):3270-9
references.pmid: 15800181
references.citation: Am J Pathol. 2001 Feb;158(2):453-68
references.pmid: 11159183
references.citation: Psychopharmacology (Berl). 1991;104(1):81-5
references.pmid: 1831909
references.citation: Brain Res Brain Res Rev. 2001 Dec;38(1-2):247-89
references.pmid: 11750934
references.citation: Neuropharmacology. 2001 Sep;41(3):360-8
references.pmid: 11522327
references.citation: Biol Psychiatry. 2008 Feb 15;63(4):349-52
references.pmid: 17643398
references.citation: Brain Res. 2005 Apr 25;1042(1):92-8
references.pmid: 15823257
references.citation: Psychoneuroendocrinology. 2003 Jan;28(1):19-34
references.pmid: 12445834
references.citation: J Mol Neurosci. 1998 Jun;10(3):219-33
references.pmid: 9770644
references.citation: Neuropharmacology. 2001 Jun;40(8):1028-33
references.pmid: 11406194
references.citation: J Neurosci. 2002 May 1;22(9):3638-44
references.pmid: 11978839
references.citation: Psychopharmacol Bull. 2001 Spring;35(2):5-49
references.pmid: 12397885
references.citation: Neuropsychopharmacology. 2006 Nov;31(11):2405-14
references.pmid: 16482087
references.citation: Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2179-84
references.pmid: 14766991
references.citation: Clin Neuropharmacol. 1988;11 Suppl 2:S43-50
references.pmid: 3052825
references.citation: Alcohol Alcohol. 1993 May;28(3):281-6
references.pmid: 8352839
references.citation: Neuropsychobiology. 1994;30(2-3):85-93
references.pmid: 7800169
references.citation: J Comp Neurol. 1985 Oct 1;240(1):37-59
references.pmid: 4056104
references.citation: Psychoneuroendocrinology. 2004 Jul;29(6):778-90
references.pmid: 15110927
references.citation: CNS Drugs. 2008;22(1):15-26
references.pmid: 18072812
references.citation: Encephale. 2003 Jul-Aug;29(4 Pt 1):322-8
references.pmid: 14615702
references.citation: Biol Psychiatry. 2004 Apr 15;55(8):789-96
references.pmid: 15050859
references.citation: Eur J Neurosci. 2003 Jun;17(11):2409-17
references.pmid: 12814372
references.citation: Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14002-8
references.pmid: 9391142
references.citation: Eur Psychiatry. 2002 Jul;17 Suppl 3:331-40
references.pmid: 15177089
references.citation: Pharmacol Res. 2001 May;43(5):411-23
references.pmid: 11394932
references.citation: Biol Psychiatry. 2006 Jun 15;59(12):1116-27
references.pmid: 16631126
references.citation: Behav Neurosci. 1996 Dec;110(6):1321-34
references.pmid: 8986335
references.citation: Eur J Pharmacol. 1995 Dec 27;294(1):125-35
references.pmid: 8788424
references.citation: CNS Drugs. 2002;16(1):65-75
references.pmid: 11772119
references.citation: J Affect Disord. 1999 Dec;56(2-3):109-18
references.pmid: 10701468
references.citation: FASEB J. 2008 Sep;22(9):3129-34
references.pmid: 18492725
references.citation: Encephale. 2002 Jul-Aug;28(4):343-9
references.pmid: 12232543
references.citation: J Neurochem. 1993 Nov;61(5):1957-60
references.pmid: 7901339
references.citation: Hum Psychopharmacol. 2001 Apr;16(3):219-227
references.pmid: 12404574
references.citation: Brain Res. 1993 Jun 25;615(1):87-94
references.pmid: 8364729
references.citation: Neuroscience. 1995 Nov;69(1):89-98
references.pmid: 8637636
references.citation: Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1387-92
references.pmid: 12552118
references.citation: Biol Psychiatry. 2003 Aug 1;54(3):338-52
references.pmid: 12893109
references.citation: Biol Psychiatry. 2004 Jun 15;55(12):1171-8
references.pmid: 15184036
references.citation: Eur J Pharmacol. 2007 Jun 22;565(1-3):68-75
references.pmid: 17368617
references.citation: Eur Neuropsychopharmacol. 2004 May;14(3):175-83
references.pmid: 15056476
references.citation: Neuropsychobiology. 1997;35(1):24-9
references.pmid: 9018020
references.citation: CNS Drugs. 2001;15(3):231-59
references.pmid: 11463130
references.citation: Eur Neuropsychopharmacol. 2004 Dec;14 Suppl 5:S481-90
references.pmid: 15550346
references.citation: Eur Psychiatry. 2002 Jul;17 Suppl 3:318-30
references.pmid: 15177088
references.citation: Eur J Neurosci. 2001 Jul;14(1):161-6
references.pmid: 11488960
references.citation: Presse Med. 1996 Mar 16;25(9):461-8
references.pmid: 8685201
references.citation: Behav Neurosci. 2008 Apr;122(2):282-92
references.pmid: 18410168
references.citation: Neuropharmacology. 2001 Aug;41(2):272-81
references.pmid: 11489464
references.citation: Curr Opin Pharmacol. 2004 Feb;4(1):4-11
references.pmid: 15018832
references.citation: Neuropharmacology. 1992 Mar;31(3):221-7
references.pmid: 1630590
references.citation: Neuropharmacology. 2004 Feb;46(2):151-9
references.pmid: 14680755
references.citation: Br J Psychiatry Suppl. 1992 Feb;(15):44-50
references.pmid: 1356357
references.citation: Int J Neuropsychopharmacol. 2009 May;12(4):553-9
references.pmid: 18976544
references.citation: Curr Drug Targets CNS Neurol Disord. 2004 Jun;3(3):181-94
references.pmid: 15180479
references.citation: Brain Res Brain Res Rev. 1999 Jan;29(1):83-120
references.pmid: 9974152
references.citation: Neuroscience. 1997 Mar;77(1):65-73
references.pmid: 9044375
references.citation: Drugs. 1995 Mar;49(3):411-39
references.pmid: 7774514
references.citation: Acta Psychiatr Scand. 1998 May;97(5):351-7
references.pmid: 9611085
references.citation: Eur Neuropsychopharmacol. 2008 Feb;18(2):87-98
references.pmid: 17566714
references.citation: J Clin Psychopharmacol. 2003 Apr;23(2):155-68
references.pmid: 12640217
references.citation: Neuropsychobiology. 1989;22(1):41-8
references.pmid: 2700774
references.citation: Curr Drug Targets CNS Neurol Disord. 2002 Jun;1(3):297-317
references.pmid: 12769621
references.citation: Pharmacol Ther. 2007 Jul;115(1):116-47
references.pmid: 17582504
references.citation: Neuropsychopharmacology. 2008 Jan;33(1):88-109
references.pmid: 17851537
references.citation: Neuropharmacology. 1990 Jan;29(1):1-8
references.pmid: 1689469
references.citation: Stress. 2006 Mar;9(1):29-40
references.pmid: 16753931
references.citation: Eur Neuropsychopharmacol. 2004 Dec;14 Suppl 5:S497-502
references.pmid: 15550348
references.citation: Brain Res. 1994 Mar 7;639(1):167-70
references.pmid: 8180832
references.citation: Eur J Pharmacol. 2000 Sep 1;403(1-2):55-65
references.pmid: 10969144
references.citation: Eur J Pharmacol. 2005 May 2;514(1):25-34
references.pmid: 15878321
references.citation: Eur J Neurosci. 2007 May;25(10):3109-14
references.pmid: 17561824
references.citation: CNS Neurol Disord Drug Targets. 2007 Apr;6(2):87-100
references.pmid: 17430147
references.citation: Eur Neuropsychopharmacol. 2002 Oct;12(5):417-25
references.pmid: 12208559
references.citation: Biol Psychiatry. 2006 Feb 1;59(3):244-51
references.pmid: 16140276
references.citation: J Neurosci. 1995 Jun;15(6):4687-92
references.pmid: 7790933
references.citation: Neuropharmacology. 1994 Aug;33(8):1011-6
references.pmid: 7531300
references.citation: Eur Psychiatry. 2002 Jul;17 Suppl 3:311-7
references.pmid: 15177087
references.citation: Biol Psychiatry. 1999 Nov 1;46(9):1181-91
references.pmid: 10560024
references.citation: Hum Psychopharmacol. 2002 Aug;17(6):299-303
references.pmid: 12404675
references.citation: Psychopharmacology (Berl). 1990;102(2):227-33
references.pmid: 2274605
references.citation: Sci STKE. 2003 Nov 04;2003(207):pe49
references.pmid: 14600293
references.citation: Ann N Y Acad Sci. 2003 Nov;1003:292-308
references.pmid: 14684453
references.citation: Neuropharmacology. 2009 Jan;56(1):37-46
references.pmid: 18657555
references.citation: Eur J Neurosci. 2002 Sep;16(5):807-16
references.pmid: 12372016
references.citation: J Neurochem. 1995 Jul;65(1):268-74
references.pmid: 7790870
references.citation: Semin Clin Neuropsychiatry. 2002 Oct;7(4):281-92
references.pmid: 12382210
references.citation: Mol Psychiatry. 2005 Jun;10(6):525-37
references.pmid: 15753957
references.citation: Br J Psychiatry Suppl. 1992 Feb;(15):51-5
references.pmid: 1356358
references.citation: Eur J Pharmacol. 1999 Apr 29;371(2-3):113-22
references.pmid: 10357248
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1995 Feb;351(2):119-25
references.pmid: 7770094
references.citation: Eur Neuropsychopharmacol. 2004 Dec;14 Suppl 5:S491-5
references.pmid: 15550347
references.citation: Neurosci Lett. 2005 Apr 22;378(3):131-4
references.pmid: 15781145
references.citation: J Neurosci. 2002 Aug 1;22(15):6810-8
references.pmid: 12151561
references.citation: Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12796-801
references.pmid: 11675510
references.citation: Cereb Cortex. 2004 Feb;14(2):224-9
references.pmid: 14704220
references.citation: Clin Neuropharmacol. 1988;11 Suppl 2:S32-42
references.pmid: 3180116
references.citation: J Neurochem. 2005 Jun;93(5):1345-52
references.pmid: 15934953
references.citation: Br J Psychiatry Suppl. 1992 Feb;(15):56-60
references.pmid: 1389023
references.citation: Eur J Pharmacol. 1992 Nov 3;222(1):157-62
references.pmid: 1468492
references.citation: Curr Med Res Opin. 2003;19(2):114-24
references.pmid: 12740155
references.citation: Psychopharmacology (Berl). 2001 Apr;154(4):356-61
references.pmid: 11349388
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1987 Nov;336(5):478-82
references.pmid: 3437921